NCT04644770 2026-04-13
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Active not recruiting
Clinical Trials
20 trialsNCT05079698 2026-04-07
A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04235777 2026-03-27
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06369246 2026-03-09
PRORAD-5 PROstate RADiation in 5 Fractions: Phase II Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer.
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04943536 2026-02-27
BiolenRT
Alessa Therapeutics Inc.
Phase 1 Active not recruiting
NCT01923506 2025-11-26
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06132945 2025-11-14
A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT01655836 2025-09-11
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
Thomas Jefferson University
Phase 1 Active not recruiting
NCT03477864 2025-04-29
Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer
Thomas Jefferson University
Phase 1 Withdrawn
NCT03835533 2024-04-12
PORTER
Parker Institute for Cancer Immunotherapy
Phase 1 Completed
NCT05259319 2023-10-17
IMMUNOs-SBRT
Centre Georges Francois Leclerc
Phase 1 Unknown
NCT05567770 2023-08-24
ACTION
Weill Medical College of Cornell University
Phase 1 Withdrawn
NCT02572284 2023-01-19
Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02206334 2022-05-25
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
NRG Oncology
Phase 1 Completed
NCT03041285 2022-05-11
Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer
Royal North Shore Hospital
Phase 1 Terminated
NCT02653248 2022-02-09
SBRT for Organ Confined Prostate Cancer
Northwell Health
Phase 1 Completed
NCT02946008 2019-11-27
Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT01943188 2017-03-15
Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer
Stanford University
Phase 1 Terminated
NCT02410174 2017-01-09
To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors
Beth Israel Medical Center
Phase 1 Terminated
NCT00445757 2012-03-20
Stereotactic Radiation Therapy in Treating Patients With Kidney Tumors
Case Comprehensive Cancer Center
Phase 1 Withdrawn